Sagar Lonial, MD, FACP - Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy

Go online to PeerView.com/VDA860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. The modern management of multiple myeloma (MM) continues to
be transformed by the emergence and further development of
immunotherapeutics, including antibody-based agents directed
against targets such as CD38 and BCMA, as well as emerging BCMA
CAR-T cell therapy options. These new “ABCs” of myeloma management
now represent the cornerstone of high-quality, collaborative care.
In this video activity, a hematologist-oncologist and an oncology
nurse will highlight the importance of interprofessional
collaboration when applying the new "ABCs" of patient management in
MM while addressing safety and efficacy evidence supporting the use
of antibodies and cellular therapy. Upon completion of this
activity, participants should be better able to: Summarize current
evidence surrounding novel and emerging immunotherapeutics,
including antibody-based and CAR-T options, for the treatment of
multiple myeloma (MM); Integrate novel antibody and cellular
therapies into team management plans for patients with newly
diagnosed or relapsed MM; and Develop team-based management plans
for addressing practical dosing/schedule, safety, care
coordination, and patient counseling considerations associated with
the use of antibody- and cell therapy-based options in the MM
setting.